Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 4/20 | 0.59 |
| ▸ | CSF1R | P07333 | 4/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 5/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381992 | 0.90 | BTK (0.69) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL17936182 | 0.86 | KIT (0.66) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL846560 | 0.86 | BTK (0.65) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL31436860 | 0.86 | BTK (0.65) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL30080653 | 0.86 | KIT (0.66) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL27783267 | 0.86 | BTK (0.62) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL3718596 | 0.85 | BTK (0.64) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL3721655 | 0.85 | BTK (0.64) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL21400972 | 0.85 | NPC1 (0.79) | BTKHDAC6LCKCSF1RMAPK14 | |
| SCHEMBL4006161 | 0.84 | BTK (0.63) | BTKHDAC6LCKCSF1RMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3333162-A1 | METOD FOR PREPARING N-(2-METHYL-5-NITROPHENYL)-4-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE | Silesian Catalysts sp. z o.o. (PL) | 2018-06-13 | — | — | EP | disclosed |
| US-9573928-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2017-02-21 | — | — | US | disclosed |
| CN-104230884-B | Imatinib intermediate and its preparation method | 北大方正集团有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-102382100-B | Preparation method of imatinib | SHANGHAI SUNRISE PHARMACEUTICAL CO LTD | 2014-04-16 | — | — | CN | disclosed |
| US-8609842-B2 | Method for synthesizing Imatinib | FUJIAN SOUTH PHARMACEUTICAL CO., LTD. (CN) | 2013-12-17 | — | — | US | disclosed |
| EP-2248807-B1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| CN-101735196-B | Method for synthesizing Imatinib | FUJIAN SOUTH PHARMACEUTICAL CO LTD | 2013-03-20 | — | — | CN | disclosed |
| WO-2013035102-A1 | PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013035102-A1 | PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2013-03-14 | — | — | WO | disclosed |
| US-20130041149-A1 | New Method for Synthesizing Imatinib | FUJIAN SOUTH PHARMACEUTICAL CO., LTD. (CN) | 2013-02-14 | — | — | US | disclosed |
| US-20070293683-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | LOISELEUR OLIVIER | 2007-12-20 | — | — | US | disclosed |
| US-20070293673-A1 | reacting an intermediate with a compound R14-H, where in R14 is methylpiperazine or salt; 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; antitumor tyrosine kinase inhibitor | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| CN-100347162-C | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2007-11-07 | — | — | CN | disclosed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | disclosed |
| CN-101016293-A | Preparing method of imatinib | HANGZHOU SHENGMEI MEDICINE TEC (CN) | 2007-08-15 | — | — | CN | disclosed |
| CN-101016262-A | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | disclosed |
| US-20060149061-A1 | Novel process for preparing Imatinib | PERRIGO API LTD. (IL) | 2006-07-06 | — | — | US | disclosed |
| US-20060142580-A1 | an N-phenyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide claimed intermediate easily prepared by amidation of the aniline and the benzoic acid; reaction with a 2-aminopyrimidine to produce antitumor tyrosine kinase inhibitor | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1630648-A | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293673-A1 | reacting an intermediate with a compound R14-H, where in R14 is methylpiperazine or salt; 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; antitumor tyrosine kinase inhibitor | ERBB4, ABL1, MAP4K4 | BTK 88/4885HDAC6 300/4885LCK 40/4885 |
| US-20070293683-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NME2, PNP, NUDT1 | BTK 2491/4885HDAC6 1369/4885LCK 1001/4885 |
| US-20060142580-A1 | an N-phenyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide claimed intermediate easily prepared by amidation of the aniline and the benzoic acid; reaction with a 2-aminopyrimidine to produce antitumor tyrosine kinase inhibitor | ERBB2, ABL1, ABL2 | BTK 83/4885HDAC6 524/4885LCK 185/4885 |
| US-20130041149-A1 | New Method for Synthesizing Imatinib | ABL1, ALK, PDGFRA | BTK 28/4885HDAC6 1360/4885LCK 53/4885 |
| US-20060149061-A1 | Novel process for preparing Imatinib | ABL1, ABL2, PDGFRA | BTK 283/4885HDAC6 3008/4885LCK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.